Macular Degeneration News and Research RSS Feed - Macular Degeneration News and Research

Macular degeneration is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving.
FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). [More]
Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today. [More]
Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone. [More]
Professor receives award for development of anti-angiogenic therapy for retinal disease

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal. [More]
Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world. [More]
New way to reduce abnormal blood vessel growth and leakage in eye

New way to reduce abnormal blood vessel growth and leakage in eye

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema. [More]
Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

The symptoms of dry eye disease include the sensation of grit in the eye, frequently accompanied by itching, burning and visual disturbance. The causes are poorly understood. [More]
iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]

Reticular pseudodrusen predicts late-stage AMD

Reticular pseudodrusen increases the likelihood of people with choroidal neovascularisation in one eye also developing late-stage, age-related macular degeneration in the other eye, researchers report. [More]
Lifestyle factors modify vision impairment risk

Lifestyle factors modify vision impairment risk

Smoking, drinking alcohol and physical activity are modifiable behaviours that influence the risk of vision impairment, show findings from the Beaver Dam Eye Study. [More]
Simple colour test could detect early onset of nAMD in the UK

Simple colour test could detect early onset of nAMD in the UK

A simple colour test that could detect the early onset of a condition which accounts for over half of visual impairment certifications in the UK is being researched by scientists at Aston University. [More]
Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

The Perelman School of Medicine at the University of Pennsylvania has launched the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to build on its previous success developing novel therapies for the personalized diagnosis and treatment of retinal and ocular disorders. [More]
Choroidal consequences differ between anti-VEGF therapies

Choroidal consequences differ between anti-VEGF therapies

Aflibercept’s possession of a fragment crystallisable region may make it more likely to induce unwanted effects in retinal and choroidal vessels than other anti-vascular endothelial growth factor therapies, say researchers. [More]
Risk factors for sporadic vision loss in AMD identified

Risk factors for sporadic vision loss in AMD identified

Sporadic vision loss occurs in patients with age-related macular degeneration and impairs their future visual acuity, research shows. [More]
Focal choroidal excavation linked to chorioretinal diseases

Focal choroidal excavation linked to chorioretinal diseases

Results of a Japanese study show that focal choroidal excavation is present in several ocular diseases, including typical age-related macular degeneration, central serous chorioretinopathy, polypoidal choroidal vasculopathy and idiopathic choroidal neovascularization. [More]

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. [More]
FGF proteins play broad roles in wound healing

FGF proteins play broad roles in wound healing

Mice missing two important proteins of the vascular system develop normally and appear healthy in adulthood, as long as they don't become injured. If they do, their wounds don't heal properly, a new study shows. [More]
Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy. [More]
Majority of adults need to double consumption of fruits and vegetables for crucial nutrition, health benefits

Majority of adults need to double consumption of fruits and vegetables for crucial nutrition, health benefits

New research published in the September issue of the British Journal of Nutrition and featured in the just released Global Phytonutrient Report highlights a significant shortfall in fruit and vegetable consumption in people's diets around the world. [More]
European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema. [More]